Johnson & Johnson is spending about $16.6 billion to buy cardiovascular technology company Abiomed and build up its medical device division.
Johnson & Johnson will spend $16.6 billion to buy cardiovascular technology company Abiomed to strengthen its medical device division.
The health care giant said Tuesday that it will pay $380 for each Biomed share and also provide another $35 per share in cash if some commercial and clinical milestones are met.
Abiomed develops technology that treats coronary artery disease and heart failure.